HIF prolyl hydroxylase inhibitors for the treatment of renal anaemia and beyond

Nature Reviews Nephrology 12, 157 (2016). doi:10.1038/nrneph.2015.193 Authors: Patrick H. Maxwell & Kai-Uwe Eckardt Small-molecule stabilizers of hypoxia inducible factor (HIF) are being developed for the treatment of renal anaemia. These molecules inhibit prolyl hydroxylase domain-containing (PHD) enzymes, resulting in HIF activation and increased production of erythropoietin. Currently, renal anaemia is treated with recombinant human erythropoietin or related analogues,
Source: Nature Reviews Nephrology - Category: Urology & Nephrology Authors: Tags: Review Source Type: research